title: Autologous antibodies that bind neuroblastoma cells.
abstract: Antibody therapy of neuroblastoma is promising and our goal is to derive antibodies from patients with neuroblastoma for developing new therapeutic antibodies. The feasibility of using residual bone marrow obtained for clinical indications as a source of tumor cells and a source of antibodies was assessed. From marrow samples, neuroblastoma cells were recovered, grown in cell culture and also implanted into mice to create xenografts. Mononuclear cells from the marrow were used as a source to generate phage display antibody libraries and also hybridomas. Growth of neuroblastoma patient cells was possible both in vitro and as xenografts. Antibodies from the phage libraries and from the monoclonal hybridomas bound autologous neuroblastoma cells with some selectivity. It appears feasible to recover neuroblastoma cells from residual marrow specimens and to generate human antibodies that bind autologous neuroblastoma cells. Expansion of this approach is underway to collect more specimens, optimize methods to generate antibodies, and to evaluate the bioactivity of neuroblastoma-binding antibodies.
authors.affiliation: Department of Surgery, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA.
authors.forename: Yujing
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA; Michigan State University, Grand Rapids, MI 49503, USA.
authors.forename: Giselle S
authors.initials: GS
authors.lastname: Sholler
authors.affiliation: Department of Surgery, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA.
authors.forename: Girja S
authors.initials: GS
authors.lastname: Shukla
authors.affiliation: Department of Surgery, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA.
authors.forename: Stephanie C
authors.initials: SC
authors.lastname: Pero
authors.affiliation: Department of Surgery, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA.
authors.forename: Chelsea L
authors.initials: CL
authors.lastname: Carman
authors.affiliation: Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA; Michigan State University, Grand Rapids, MI 49503, USA.
authors.forename: Ping
authors.initials: P
authors.lastname: Zhao
authors.affiliation: Department of Surgery, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA. Electronic address: david.krag@uvm.edu.
authors.forename: David N
authors.initials: DN
authors.lastname: Krag
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D006801:Humans; D006825:Hybridomas; D007963:Leukocytes, Mononuclear / Q000276:immunology; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009447:Neuroblastoma / Q000276:immunology*; D019151:Peptide Library; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D019151:Peptide Library
keywords: Antibody; Bone marrow; Hybridoma; Neuroblastoma; Phage display